INanoBio is a pioneering nano-biotechnology company based in Phoenix, Arizona. As a spin-off of Arizona State University, we are dedicated to commercializing the groundbreaking FDEC FET nano sensor technology. Our mission is to revolutionize healthcare diagnostics, genome sequencing, and industrial and security sensing.

In the realm of genome sequencing, we are developing an advanced 3D nanopore-transistor device. This device, based on CMOS semiconductor nanotechnology, will enable the accurate sequencing of the entire human genome at a fraction of the current cost and time. It will be over 100 times faster than existing protein nanopore-based sequencers, allowing us to sequence whole populations around the globe.

Furthermore, INanoBio is committed to detecting diseases in their earliest stages, which dramatically improves therapeutic outcomes. Through our advanced nano-biotechnology tools, we can discover disease-specific molecular biomarkers and detect them in blood with unprecedented sensitivity. We are working on simple blood tests that can detect cancers early, eliminating the need for invasive biopsies.

Led by a highly qualified team and supported by renowned scientific advisory board members, we at INanoBio are at the forefront of developing transformative technologies for early-stage disease diagnostics. With our innovative platforms and machine learning capabilities, we aim to usher in a new era of preemptive medicine within the next few decades. For more information about INanoBio and our groundbreaking work, please visit our website or contact us using the provided information